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Abstract
The benefits of long-term peritoneal dialysis (PD) in patients with end-stage renal failure are short-lived due to structural
and functional changes in the peritoneal membrane. In this report, we provide evidence for the in vitro and in vivo
participation of the renin-angiotensin-aldosterone system (RAAS) in the signaling pathway leading to peritoneal fibrosis
during PD. Exposure to high-glucose PD fluids (PDFs) increases damage and fibrosis markers in both isolated rat peritoneal
mesothelial cells and in the peritoneum of rats after chronic dialysis. In both cases, the addition of the RAAS inhibitor
aliskiren markedly improved damage and fibrosis markers, and prevented functional modifications in the peritoneal
transport, as measured by the peritoneal equilibrium test. These data suggest that inhibition of the RAAS may be a novel
way to improve the efficacy of PD by preventing inflammation and fibrosis following peritoneal exposure to high-glucose
PDFs.
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Introduction
Chronic kidney disease is a worldwide public health problem
with increasing incidence and prevalence, poor outcomes and high
costs [1] Long-term peritoneal dialysis (PD) is a suitable and
effective therapy option for patients with end-stage renal failure,
and has been widely used for more than 20 years [2]. Nevertheless,
the benefits of PD are short-lived, mainly due to structural and
functional changes in the peritoneal membrane caused by the use
of conventional PD fluids (PDFs) [3,4], which contain high
concentrations of glucose as the osmotic agent [5,6]. However, a
loss of peritoneal mesothelial cells (PMCs), progressive peritoneal
fibrosis (PF), membrane hyperpermeability and ultrafiltration
failure develop when using glucose-based solutions [7–9], although
the physiopathological mechanisms underlying these changes are
not fully understood.
Angiotensin II, a component of the renin–angiotensin–aldoste-
rone system (RAAS), is constitutively expressed within PMCs
[10,11]. Noxious stimuli induce activation of the local peritoneal
angiotensin II, which initiates production of transforming growth
factor-b1 (TGF-b1), thus contributing to extracellular matrix
accumulation and inducing PF [12,13]. Functionally, these
changes translate into reduced ultrafiltration capacity of the
peritoneal membrane, which is a significant cause of the failure of
the technique among patients on long-term PD [11]. Aliskiren
decreases angiotensin II production [14] and it is therefore
effective in lowering blood pressure and holds considerable
potential for organ protection beyond blood pressure reduction
[14,15].
We studied the protective effects of aliskiren on PMCs exposed
to glucose-enriched solutions in vitro as well as on the peritoneal
membrane in rats dialyzed with PDFs for four weeks. We found
that, at concentrations achievable in humans, aliskiren prevents
high glucose-mediated PDF-induced thickening and fibrosis of the
peritoneum, decreases cellular damage markers and, by decreasing
fibrosis, preserves the efficacy of PDFs. These results strongly
suggest that a RAAS blockade may increase the effective time of
PDF therapy, paving the way for the development of new, less
toxic PD solutions.
Results
Aliskiren Protects PMCs From PDF Toxicity In Vitro
In cultured rat PMCs, PDFs containing high levels of glucose
induced increases in free-radical production that amounted to
approximately 162.568.5% of control levels at 8 h of exposure
(Fig. 1a). Phosphorylation of p38 mitogen-activated protein kinase
(MAPK) is a generally accepted index of toxicity for PMCs [16].
Exposure to a high-glucose PDF for 48 h caused a marked
increase in the phospho-p38 (p-p38) MAPK/p38 MAPK protein
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36268ratio compared to control cells (Fig. 1b). This toxicity may activate
the cell death cascade, as indicated by the increase in caspase-3
activity observed in rat PMCs following exposure to a high-glucose
PDF for 18 h (Fig. 1c). Aliskiren, at concentrations equal to or
higher than 50 mmol/L, significantly prevented the observed
increase in the studied toxicity markers for PMCs in vitro (Fig. 1).
Moreover, exposure to a high-glucose PDF for 24 h caused a
marked increase in mRNA levels of the pro-apoptotic markers p53
(Fig. 2a) and Bax (Fig. 2b), and a decrease in the mRNA level of
the anti-apoptotic marker Bcl-2 (Fig. 2c) in rat-cultured PMCs. On
the other hand, exposure to a high-glucose PDF for 24 h increased
mRNA levels of fibrosis markers such as collagen III (Fig. 2d) and
fibronectin (Fig. 2e). RAAS inhibition using aliskiren markedly
decreased the production of these fibrosis and pro-apoptotic
markers, as well and increased Bcl-2 mRNA expression (Fig. 2).
Aliskiren Prevents Damage Induced In Vivo by High-
Glucose PDFs
To explore PDF-mediated toxicity in vivo, we dialyzed rats daily
using commercial PDFs containing three different glucose
concentrations (1.5%, 2.3% and 4.5%) for four weeks. At the
end of the study, the peritoneum was removed and analyzed for
levels of mRNA encoding for proteins involved in the death/
survival pathway. The p53 mRNA levels increased in PMCs
collected from the peritoneum of rats dialyzed with 4.5% PDF as
compared to the vehicle group (Fig. 3a). The addition of aliskiren
(100 mg/l) to the PD solution prevented the PDF-mediated
increase in p53 mRNA levels (Fig. 3a). Moreover, Bax mRNA
levels were significantly higher in the rat peritoneum after chronic
dialysis than in the vehicle-dialyzed group. The increase in Bax
mRNA levels following dialysis was much smaller when aliskiren
was added to the PDF (Fig. 3b), with a concentration-dependent
effect from aliskiren. The above data indicate that aliskiren
prevents the PDF-induced increase in pro-apoptotic gene
expression. In addition, chronic dialysis using 2.3% and 4.5%
PDFs decreased mRNA levels of the anti-apoptotic protein Bcl-2
in the peritoneum (Fig. 3c). The addition of aliskiren to the PD
solution markedly increased Bcl-2 mRNA levels well above basal
levels (between 2- and 5-fold) (Fig. 3c). Surprisingly, this effect was
not observed in vehicle-dialyzed rats and was only evident
Figure 1. Aliskiren decreases toxicity induced by peritoneal dialysis fluids (PDFs) in rat peritoneal mesothelial cells (PMCs). a) Effect
of aliskiren on PDF-mediated reactive oxygen species (ROS) production in PMCs. Cells were treated for 8 h with a 1.5%-glucose PDF diluted 1:1 in
culture medium in the absence (V) or the presence of aliskiren. ROS production was measured using dichlorodihydrofluorescein (DCF) as described in
Methods. Results represent mean 6 s.e.m. of 4 experiments. *p,0.05 as compared to untreated control cells (C).
#p,0.05 as compared to cells
treated with vehicle and high-glucose PDF (V). b) Effect of aliskiren on phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK)/p38 MAPK ratio
in rat PMCs exposed to a high-glucose PDF for 24 h. PMCs were treated as above, in the absence (V) or presence of aliskiren and then both p-p38
MAPK and p38 MAPK protein levels were determined by western blot. The histograms represent a densitometric analysis of the p-p38 MAPK/p38
MAPK ratio. Data represent mean 6 s.e.m. of 4 experiments.*p,0.05 as compared to C. #p,0.01 as compared to V. c) Effect of aliskiren on caspase-3
activity in rat PMCs exposed to a high-glucose PDF for 18 h. PMCs were treated as above, in the absence (V) or presence of aliskiren and then
caspase-3 activity was determined (see Methods). Data represent mean 6 s.e.m. of 4 experiments. *p,0.05 as compared to C.
#p,0.05 as compared
to V.
doi:10.1371/journal.pone.0036268.g001
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bio-incompatible PD solutions may sensitize peritoneal cells to the
actions of aliskiren.
Aliskiren Reduces Inflammation and Fibrosis Produced by
High-Glucose PDFs
After four weeks of daily PD, a Peritoneal Equilibrium Test
(PET) adjusted for rats was performed using 2.3% PDF. The C
reactive protein (CRP) and amyloid-P protein level inflammation
markers were increased in both serum and dialysate when the rats
were dialyzed using 4.25% PDF in the absence of aliskiren (Figs. 4a
and 4b). Moreover, amyloid-P protein levels were also significantly
increased in the group dialyzed with 2.3% PDF. The addition of
aliskiren (100 mg/l) to the PDFs prevented the increase observed
in the levels of inflammation markers CRP and amyloid-P protein
in both serum and dialysate (Figs. 4c and 4d).
Consistent with well-known PD complications, fibrosis markers
such as fibronectin and collagen III mRNA levels were markedly
elevated in PMCs collected from the 2.3% and 4.25% PDF groups
when compared to the vehicle group (Figs. 5a and 5b). These
changes in fibronectin and collagen III gene expression after PDF
exposure correlated with an increase in the thickness of the
peritoneal membrane (Fig. 5c). The inclusion of aliskiren in the PD
solution markedly reduced fibronectin and collagen III mRNA
levels in response to chronic dialysis with the 2.3% and 4.25%
PDFs and decreased the thickness of the peritoneal membrane
after chronic dialysis (Fig. 5).
Aliskiren Inhibits High-Glucose PDF-Mediated Changes in
Peritoneal Solute Transport
There was no significant difference in D2/D0 glucose and D2/
P2 creatinine ratios between the groups dialyzed with vehicle in the
absence or presence of aliskiren (Fig. 6). The peritoneal solute
transport in the group dialyzed with 1.5% PDF for four weeks was
no different from that observed in the group dialyzed with saline
alone (vehicle group), and the presence of different doses of
aliskiren in the 1.5% PDF did not have any effect. On the other
hand, D2/D0 glucose ratios were significantly lower, and D2/P2
creatinine ratios were significantly higher in the 2.3% and the
4.25% PDF groups as compared to the vehicle group (Fig. 6)
indicating a high transporter status that is consistent with the
observed inflammatory changes. The groups dialyzed with both
2.3% and 4.25% PDFs supplemented with aliskiren showed higher
D2/D0 glucose and lower D2/P2 creatinine ratios than their
Figure 2. Aliskiren decreases fibrosis markers and inhibits changes in apoptosis markers induced by peritoneal dialysis fluids
(PDFs) in rat peritoneal mesothelial cells (PMCs). Cells were treated for 24 h with a 1.5%-glucose PDF diluted 1:1 in culture medium in the
absence (V) or the presence of aliskiren, and the levels of mRNA for p53 (a), Bax (b), Bcl-2 (c), collagen III (d) and fibronectin (e) were determined by
real-time RT-PCR. Data represent mean 6 s.e.m. of 4 experiments. *p,0.05 as compared to untreated control cells (C).
#p,0.01 as compared to cells
treated with vehicle and PDF (V).
doi:10.1371/journal.pone.0036268.g002
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of aliskiren indicating a lower transporter status. Moreover, the
effect of aliskiren was dose-dependent, with a significantly higher
D2/D0 glucose ratio and a significantly lower D2/P2 creatinine
ratio in the group dialyzed with 4.25% PDF supplemented with
100 mg/l aliskiren than the group dialyzed with 4.25% PDF
supplemented with 10 mg/l aliskiren (Fig. 6).
Discussion
PD is an effective therapy for patients with end-stage renal
failure [8]. Nevertheless, the benefits of PD are short-lived, due
mainly to structural and functional changes in the peritoneal
membrane caused by the use of conventional high-glucose PDFs.
These changes can cause deterioration of the peritoneal
membrane, thereby inducing a failure in peritoneal transport of
solutes and ultrafiltration [17]. This failure results in patients
having to turn to hemodialysis therapy for end-stage renal failure,
and enduring the medical, social and economic limitations related
to this type of treatment.
There is substantial evidence to support a pathogenic role of
high-glucose PDFs in the development of structural and functional
alterations in the peritoneum of long-term PD patients, including
an increase in oxidative stress, p38 MAPK activity and apoptosis
[18,19]. Previous studies have shown that all these PMC damage
markers are increased in PMCs exposed to high-glucose solutions
in a dose- and time-dependent manner [19,20]. We observed in
our study that rat PMCs exposed in vitro to a high-glucose PDF
showed increases in damage markers, such as reactive oxygen
species (ROS) production, p38 MAPK phosphorylation, caspase-3
activity and mRNA expression of p53 and Bax. The addition of
Figure 3. In vivo effect of aliskiren on p53, Bax and Bcl-2 mRNA levels in the peritoneum after daily peritoneal dialysis for 4 weeks.
Twelve groups of 6 rats each one were dialyzed daily as described in Methods for 4 weeks in the absence (black histograms) and in the presence of
aliskiren (10 and 100 mg/L). At the end of this period, peritoneal mesothelial cells (PMCs) were isolated and the mRNA levels for p53 (a), Bax (b), and
Bcl-2 (c) quantified and normalized to the the b-actin mRNA levels. The dialysis fluid and the treatment for each group is indicated in the graph. Each
histogram represents mean 6 s.e.m. of 6 animals. *p,0.05 as compared to the vehicle group.
#p,0.05 for the aliskiren-treated groups as compared
to the same PDF in absence of aliskiren.
$p,0.05 as compared to 10 mg/L aliskiren groups.
doi:10.1371/journal.pone.0036268.g003
Figure 4. Aliskiren decreases the levels of inflammatory markers in vivo in both serum and dialysate after chronic peritoneal
dialysis. The groups of animals were the same as in Fig. 3. A Peritoneal Equilibration Test (PET) was performed for 2 h at the end of the 4 weeks of
dialysis. The levels of amyloid-P protein (a, b) and C-reactive protein (c, d) were determined in both serum (a, c) and dialysate (b, d) collected after 2h
dwell time. The dialysis fluid used and the treatment for each group is indicated in the graph. Each histogram represents mean 6 s.e.m. of 6 animals.
*p,0.05 as compared to the vehicle group. **p,0.01 as compared to the vehicle group.
#p,0.05 for the aliskiren-treated groups as compared to the
same PDF in absence of aliskiren.
$p,0.05 as compared to 10 mg/L aliskiren groups.
doi:10.1371/journal.pone.0036268.g004
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PMCs in culture suggesting that a blockade of angiotensin
synthesis may be beneficial during PD by protecting PMCs from
high-glucose PDF-mediated damage. These protective actions of
aliskiren may be explained by the known growth factor properties
of angiotensin II, which when over-produced may cause PF [12].
Moreover, angiotensin receptor blockers and angiotensin convert-
ing-enzyme inhibitors ameliorate chlorhexidine gluconate-induced
PF in rats [21]. On the other hand, high-glucose-induced
angiotensin II synthesis has been observed in cardiac fibroblasts
[22], vascular smooth muscle cells [23] and renal mesangial cells
[24], among others. Furthermore, angiotensin II produced by
PMCs mediates high-glucose PDF-induced up-regulation of TGF-
b1 and fibronectin expression and this up-regulation is mediated
by ROS [10]. Aliskiren inhibits angiotensin I generation from
angiotensinogen by inhibiting renin leading to decreased angio-
tensin II production [14]. In vitro studies have shown that local
RAAS is physiologically active in many cell types, including
PMCs. An RAAS inhibitor could therefore be a powerful tool for
preserving peritoneal function during PD.
As with our results, previous studies have shown that the
deleterious effect of chronic PD using PDFs with elevated glucose
levels is characterized by the activation of apoptotic processes,
accumulation and deposition of excess matrix proteins within the
interstitial area, neoangiogenesis and vasculopathy of the perito-
neal microvasculature [25,26]. In our study, we analyzed the effect
of aliskiren addition to PD solutions during chronic (28 days)
dialysis of rats. We found that PMCs isolated from the peritoneum
of rats dialyzed daily for four weeks showed increased mRNA
levels of fibrosis (collagen III and fibronectin) and pro-apoptotic
(p53 and BAX) markers, as well as decreased Bcl-2 mRNA (an
anti-apoptotic marker), similar to that observed in acutely isolated
cultured PMCs in vitro, indicating that the response to high-glucose
PDFs is similar in vitro and in vivo. This expression pattern suggests
that, during chronic PD, PMCs suffer damage that activates
death-signaling pathways. However, in rats treated with aliskiren-
containing PDFs, changes in those cell damage markers were
Figure 5. Aliskiren reduces the peritoneal fibrosis in vivo after chronic peritoneal dialysis. The groups of animals were the same as in
Fig. 3. At the end of the 4 week-dialysis period, peritoneal mesothelial cells (PMCs) were isolated and the fibronectin (a) and collagen III (b) mRNA
levels were determined in PMCs and normalized to the b-actin mRNA levels. The dialysis fluid used and the treatment for each group is indicated in
the graph. Each histogram represents mean 6 s.e.m. of 6 animals. *p,0.05 as compared to the vehicle group.
#p,0.05 for the aliskiren-treated
groups as compared to the same PDF in absence of aliskiren.
$p,0.05 as compared to 10 mg/L aliskiren groups. c) Masson’s trichrome staining of
parietal peritoneum. Top panel. Histological sections from the vehicle, 1.5%-PDF, 2.3%-PDF, 4.25%-PDF, 2.3%-PDF plus aliskiren (100 mg/L) and
4.25%-PDF plus aliskiren (100 mg/L) groups at 2006magnification. Bottom panel. Quantification of the peritoneal thickness. The dialysis fluid used
and the treatment for each group is indicated in the graph. Each histogram represents mean 6 s.e.m. of 6 animals. ***p,0.001 as compared to the
vehicle group.
##p,0.01 for the aliskiren-treated groups as compared to the same PDF in absence of aliskiren.
$$p,0.01 as compared to 10 mg/L
aliskiren groups.
doi:10.1371/journal.pone.0036268.g005
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glucose peritoneal dialysis fluids. The groups of animals were the same as in Fig. 3. A Peritoneal Equilibration Test (PET) was performed for
2 hours at the end of the 4 weeks of dialysis and the ratios D2/D0 glucose level (a) and D2/P2 creatinine level (b) were determined. The dialysis fluid
used and the treatment for each group is indicated in the graph. Each histogram represents mean 6 s.e.m. of 6 animals. *p,0.05 as compared to the
vehicle group.
#p,0.05 for the aliskiren-treated groups as compared to the same PDF in absence of aliskiren.
$p,0.05 as compared to 10 mg/L
aliskiren groups.
doi:10.1371/journal.pone.0036268.g006
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showing that aliskiren suppressed in vivo gene expression of pro-
apoptotic factors inhibiting degeneration [27,28]. Taken as a
whole, these data indicate that aliskiren may protect PMCs in vivo,
which would be useful to extending the period during which PD
may be used without peritoneal damage and thus delaying the
initiation of hemodialysis.
After peritoneal membrane injury (especially to the mesothelial
cell layer), a process of tissue repair begins. This process can be
described as an inflammatory response that is characterized by
remesothelialization of the wounded area, neovascularization and
fibrosis of the submesothelial cell extracellular matrix [29]. We
observed that levels of fibrosis markers fibronectin and collagen III
mRNAs were significantly lower in PMCs collected from animals
dialyzed with PDFs containing aliskiren than in control animals
dialyzed with PDFs lacking aliskiren. Accordingly, high-glucose
PDFs also increased the thickness of the peritoneum, as well as
serum and dialysate CRP (one of the acute phase proteins whose
levels increase during systemic inflammation) and amyloid-P
protein (an acute phase protein during inflammation that can
bind to apoptotic and necrotic cells) levels. All these changes were
at least partially reversed by the addition of aliskiren to the PDFs.
This result supports the idea that aliskiren protects PMCs from
PDF-induced damage, thus decreasing the inflammation and
fibrosis associated with peritoneal PMC damage.
One important issue is whether these protective actions of
aliskiren are correlated with improved peritoneal membrane
function during PD. To explore this issue, we performed a PET,
which reflects the rates of glucose and creatinine transfer through
the peritoneal membrane, after four weeks of PD using high-
glucose PD solutions. Chronic dialysis using high-glucose PDFs
produced a glucose-dependent decrease in the D2/D0 glucose
ratio and an increase in the creatinine D2/P2 ratio, indicating a
high transporter status. This type of transport is generally
associated with less efficient ultrafiltration due to the more rapid
absorption of glucose and an earlier loss of the osmotic driving
force for fluid transport across the peritoneal membrane [5], which
leads to an early transfer to hemodialysis due to failure of the PD
[30]. In addition, a high transporter status is also associated with
reduced survival of patients receiving PD [31]. The addition of
aliskiren to the PDFs during chronic dialysis markedly increased
the D2/D0 glucose ratio while decreasing the creatinine D2/P2
ratio, thus slowing the transport rate to values obtained in rats
dialyzed with vehicle, which was due to the protective action on
PMCs against PDF-induced damage. This indicates that the
addition of aliskiren markedly improves the efficacy of PD,
probably by preventing PMC damage and subsequent inflamma-
tion and fibrosis following peritoneal exposure to high-glucose
PDFs.
We therefore propose that inhibition of the RAAS by aliskiren
protects against high-glucose PDF-induced oxidative stress,
apoptosis, inflammation, and fibrosis in vitro and in vivo. Moreover,
the addition of aliskiren to PDFs prevents alterations in peritoneal
transport as measured by the PET. These data suggest that
inhibition of the RAAS may be a novel solution for preventing
long-term PD-related modifications in the peritoneal membrane,
thereby improving the efficacy of PD.
Materials and Methods
Materials
All chemicals, unless otherwise stated, were obtained from
Sigma-Aldrich Chemical Company (St. Louis, MO, USA), and all
tissue culture plastics were purchased from TPP (Trasadingen,
Switzerland).
Animals
Seventy-two female Sprague–Dawley rats weighing 200 g to
220 g (Charles River Breeding Laboratories) were used for in vivo
experiments. The animals were housed at a constant room
temperature, with 12-hour light and dark cycles. Food and water
were given ad libitum. All experimental protocols were carried out
in accordance with the European Community Council Directive
2003/65/CE and with the experimental protocols approved by
the CHU Albacete Institutional Animal Care and Use Committee.
Dialysis Experimental Design
Rats were randomly divided into 12 groups of 6 animals each.
Four different dialysates were used: Vehicle (saline), 1.5% glucose
PDF (1.5% PDF; CAPD/DPCA 2, Fresenius Medical Care, St.
Wendel, Germany), 2.3% glucose PDF (2.3% PDF; CAPD/
DPCA 4, Fresenius Medical Care) and 4.25% glucose PDF (4.25%
PDF; CAPD/DPCA 3, Fresenius Medical Care). Each dialysate
was administrated to three different groups incorporating aliskiren
at 0 mg/l, 10 mg/l (low-dose) or 100 mg/l (high-dose) in the
dialysate. The animals received 20 ml dialysate via a 30-gauge
needle daily for four weeks. Furthermore, a group of animals was
not dialyzed and the data obtained were not significantly different
from animals dialyzed with vehicle (data not shown). Body weight
was monitored at the beginning and the end of the experimental
period. No rats were lost and all animals appeared to be healthy
during the study, which involved repeated infusions of PDF.
Peritoneal Equilibration Test (PET)
After four weeks of treatment with the dialysates, a PET was
performed during a 2-hour dwell with a 2.3% glucose PD solution.
PETs were also performed on rats from the control group. During
each PET, rats were given 30 ml of conventional 2.3% PDF
(Fresenius Medical Care) via a 30-gauge needle to the peritoneal
cavity. Dialysate samples (1 ml) were taken at time 0 (immediately
after infusion) and 120 minutes after infusion. Blood samples were
taken from the tail vein at the start and end of the PET. During
the PET, animals were awake and had free access to water and
food.
The dialysate and blood samples were centrifuged and stored at
220uC until assayed. Concentrations of creatinine and glucose in
serum and dialysate were measured using enzymatic methods on a
DSX automated analyzer (DYNEX Technologies Inc., Chantilly,
VA, USA). Amyloid-P protein and CRP quantification in serum
and dialysate were measured using ELISA kits (GenWay Biotech
Inc., San Diego, CA, USA). Peritoneal solute transport was
calculated from the dialysate concentration at 2 h relative to its
concentration in the initial infused dialysis solution (D2/D0
glucose) for glucose, and the dialysate-to-plasma concentration
ratio (D2/P2 creatinine) at 2 h for creatinine.
At the end of the PET, animals were euthanized and biopsies of
the parietal peritoneum were taken for light microscopy. Rat
PMCs were also isolated from the parietal peritoneum and
cultured as described below. Similar samples were taken from rats
not exposed to PD solution. Peritoneal thickness was determined
in Masson’s trichrome stained tissue specimens by measurement of
the combined thickness of the mesothelium and submesothelial
interstitium using a 2006 objective lens via a computer imaging
analysis system (Image-Pro Plus, Media Cybernetics, Bethesda,
MD, USA) as described previously [32]. The thickness of the
parietal peritoneum was measured at a minimum of 10 points in
each sample.
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Rat PMCs were isolated from the peritoneum of rats by
enzymatic digestion as previously described [33]. To identify
PMCs, the cells were examined for specific markers and
morphology as described elsewhere [33]. Cells between passages
3 and 6 were used for experiments. Experimental procedures were
carried out according to the guidelines of the European
Community on Welfare of Research Animals (Directive 2003/
65/CE) and the CHU Albacete Institutional Animal Care and Use
Committee.
To determine the effect of high-glucose solutions, subconfluent
PMCs were incubated with serum-free media for 24 h to arrest
and synchronize cell growth as previously described [34]. The
PMCs were then treated for 48 h with serum-free media
containing aliskiren (10 mmol/l to 100 mmol/l) or vehicle (distilled
water), before stimulation with a 1.5% glucose PDF diluted to
twice the volume with serum-free M199 medium in the presence
or absence of aliskiren.
Reactive Oxygen Species (ROS) Determination
Intracellular formation of ROS was detected using 5-(and-6)-
chloromethyl-2,7-dichlorodihydrofluorescein diacetate (DCF
[CM-H2DCFDA: Invitrogen, Barcelona, Spain]), as previously
described [35]. DCF was added at a final concentration of
10 mmol/l, and the cells were incubated for 60 minutes at 37uCi n
the dark. Cells were then washed, resuspended in PBS, and kept
on ice for immediate detection by flow cytometry (BD-LSR, BD
Biosciences, San Jose, CA, USA). Data were acquired and
analyzed using the CellQuest program (BD Biosciences).
Western Blot Analysis
Proteins (20 mg/lane) were separated on 10% polyacrylamide-
SDS gels in reducing conditions [36]. After electrophoresis,
samples were transferred onto nitrocellulose membranes (Bio-
Rad Laboratories, Hercules, CA, USA), blocked with 5% nonfat
milk in blocking TTBS buffer (50 mmol/l Tris HCl, 150 mmol/l
NaCl, and 0.05% Tween 20; pH 7.5), and incubated overnight at
4uC with a mouse monoclonal anti-p-p38 MAPK antibody
(1:1.000, Cell Signaling, Beverly, MA, USA) or a rabbit polyclonal
anti-p38 MAPK antibody (1:1000, Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Afterwards, blots were washed and
incubated at room temperature for 1 h with a secondary antibody
and developed using an enhanced chemiluminescence system
(Millipore, Bedford, MA, USA). Densitometric analysis of
immunoreactive bands was performed using Quantity One
Software (Bio-Rad Laboratories).
Caspase-3 Activity
Caspase-3 activity was determined as previously described [37].
Cell extracts (40 mg of protein) were incubated in reaction buffer
(25 mmol/l HEPES, 10% sucrose, 0.1% CHAPS buffer, and
10 mmol/l DTT) containing 50 mmol/l fluorescence substrate
Asp-Glu-Val-Asp-7-amino-4 trifluoromethyl-coumaryl (Z-DEVD-
AFC) at 37uC for 1 h. Cleavage of the AFC fluorophore was
determined at 37uC on an Infinite 200 microplate reader (Tecan
Group, Salzburg, Austria) at an excitation wavelength of 400 nm
and a fluorescence emission wavelength of 505 nm.
Real-time RT-PCR Analysis
RNA expression was evaluated by real-time RT-PCR in
cultured PMCs isolated from rats used for in vivo experiments.
cDNA was synthesized from the purified total RNA using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s instruc-
tions. For real-time RT-PCR, cDNA was amplified using SYBR
Green PCR Master mix with the StepOne Real-Time PCR
System and StepOne v2.0 software (Applied Biosystems). The
following primer sets were used to amplify: fibronectin, 59-GCA-
CAG-GGG-AAG-AAA-AGG-AG-39 (sense) and 59-TTG-AGT-
GGA-TGG-GAG-GAG-AG-39 (antisense); collagen III, 59-ATA-
TCA-AAC-ACG-CAA-GGC-39 (sense) and 59-GAT-TAA-AGC-
AAG-AGG-AAC-AC-39 (antisense); p53, 59-CCT-CCT-CAG-
CAT-CTT-ATC-CG-39 (sense) and 59-CAC-AAA-CAC-GCA-
CCT-CAA-A-39 (antisense); Bax, 59-GAT-GCG-TCC-ACC-
AAG-AA-39 (sense) and 59-AGT-AGA-AGA-GGG-CAA-CCA-
C-39 (antisense); and Bcl-2, 59-CCC-AAG-GGA-AGA-CGA-TG-
39 (sense) and 59-GAG-CGG-GTA-GGG-AAA-GA-39(antisense).
The real-time RT-PCR reaction was maintained at 95uC for
10 minutes, followed by 40 cycles of 95uC for 15 seconds and
60uC for 1 minute. The dissociation curves were analyzed to
ensure amplification of a single PCR product. In order to ensure
reliability of the results, all samples were processed in triplicate.
Quantification was performed by the comparative cycle threshold
(Ct) method [38]. To normalize the data, the b-actin RNA
expression level was used as a housekeeping gene.
Statistical Analysis
Statistical significance was evaluated by nonparametric variance
analysis (Kruskal-Wallis) followed by Dunn’s test, with p,0.05
considered statistically significant. The SPSS software application
(version 13.0: SPSS, Chicago, IL) was used for all statistical
analyses.
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